Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2000-02-08
2004-03-09
Nolan, Patrick J. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C514S013800
Reexamination Certificate
active
06703021
ABSTRACT:
TECHNICAL FIELD
The present invention relates to new uses for &agr;-fodrin and &agr;-fodrin fragment proteins.
BACKGROUND ART
Sjögren's syndrome is said to be an autoimmune disease whose cardinal manifestation is a sicca syndrome associated with keratoconjunctivitis sicca and chronic sialadenitis but the mechanisms of its onset remain to be elucidated.
Diagnosed as Sjögren's syndrome is either a glandular (primary) syndrome which is confined to the lacrimal and salivary glands and clinically characterized by the so-called dry eye/dry mouth symptom or an extraglandular (secondary) syndrome characterized by a broad spectrum of generalized symptoms involving the liver, lung, thyroid gland, pancreas, kidney, and other organs. It is also known that the glandular syndrome progresses to the extraglandular syndrome in many cases and, though rarely, gives rise to malignant lymphoma.
As autoantibodies detected in Sjögren's syndrome, SS-A/Ro and SS-B/La are known. The corresponding antigens of these antibodies have already been identified but their specificity is low, with patients possessing autoantibodies to these antigens accounting for 40-60% of the total population of patients with Sjögren's syndrome. Moreover, in many cases SS-A/Ro- or SS-B/La-positive patients have complications such as systemic lupus erythematosus and rheumatism [Journal of Clinical Investigation, 87, p68-76, 1991; and Nucleic Acids Research, 17, p2233-2244, 1989].
In view of the above findings, those antibodies or antigens are regarded as indicators of all autoimmune diseases inclusive of Sjögren's syndrome. However, neither a specific autoantigen nor a specific autoantibody that could be a specific indicator of primary Sjögren's syndrome is not heretofore known.
&agr;-Fodrin is one of subunits of fodrin which is a macromolecular actin-binding protein present immediately beneath the plasma membrane of cells. Fodrin forms high-order structures such as the fodrin network and is considered to be associated with the morphogenesis of cells and the migration of secretory granules to the surface membrane.
It has recently been reported that in programmed cell deaths such as apoptosis, the full-length &agr;-fodrin of 240K is restrictively cleaved by proteases to yield &agr;-fodrin protein fragments [Journal of Biological Chemistry, 270, p6425-6428, 1995]. Moreover, as the proteases causing such restricted cleavage of &agr;-fodrin, trypsin, chymotrypsin, and calpain are known [Journal of Neuroscience, 8, p.2640-2651, 1988].
However, the relationship of this restricted cleavage of &agr;-fodrin to Sjögren's syndrome remains to be known.
Therefore, if an autoantibody or autoantigen specific to Sjögren's syndrome, particularly primary Sjögren's syndrome, is discovered, not only will the diagnosis of Sjögren's syndrome be facilitated and made more definite but the prophylaxis and therapy of Sjögren's syndrome, particularly primary Sjögren's syndrome, and, hence, prevention of progression of primary to secondary syndrome will be made possible by establishing a tolerance to autoantigens prior to onset of the disease or after the onset.
Furthermore, detailed analyses for elucidation of the mechanisms of onset of Sjögren's syndrome will also become feasible.
SUMMARY OF THE INVENTION
In view of the above state of the art, the inventors of the present invention did much research and not only discovered autoantibodies which are specifically detected in primary Sjögren's syndrome but also found that the corresponding autoantigens are &agr;-fodrin and &agr;-fodrin fragment proteins.
The inventors further found that Sjögren's syndrome can be prevented and cured by administering such an autoantigen.
The present invention, therefore, is directed to:
(1) A pharmaceutical composition comprising &agr;-fodrin, a mutein thereof, a fragment thereof, or a salt thereof with a pharmaceutically acceptable carrier,
(2) A composition for preventing or treating autoimmune disease comprising &agr;-fodrin, a mutein thereof, a fragment thereof, or a salt thereof with a pharmaceutically acceptable carrier,
(3) A composition for preventing or treating Sjögren's syndrome comprising &agr;-fodrin, a mutein thereof, a fragment thereof, or a salt thereof with a pharmaceutically acceptable carrier,
(4) The composition described in the above item (3) wherein the molecular weight of said &agr;-fodrin, a mutein thereof, or a fragment thereof is from about 2K to about 240K,
(5) The composition described in the above item (3) wherein said &agr;-fodrin, a mutein thereof, or a fragment thereof contains or comprises an amino acid sequence substantially shown by Arg-Gln-Lys-Leu-Glu-Asp-Ser-Tyr-Arg-Phe-Gln-Phe-Phe-Gln-Arg-Asp-Ala-Glu-Glu-Leu, (SEQ ID NO: 1)
(6) The composition described in the above item (5) wherein the molecular weight of said &agr;-fodrin, a mutein thereof, or a fragment thereof is from about 100K to about 140K,
(7) The composition described in the above item (3) wherein said &agr;-fodrin fragment is an &agr;-fodrin fragment protein available upon proteolysis of &agr;-fodrin with a protease,
(8) A diagnostic agent for autoimmune disease comprising &agr;-fodrin, a mutein thereof, a fragment thereof, or a salt thereof,
(9) A diagnostic agent for Sjögren's syndrome comprising &agr;-fodrin, a mutein thereof, a fragment thereof, or a salt thereof,
(10) The diagnostic agent for Sjögren's syndrome described in the above item (9) wherein the molecular weight of &agr;-fodrin, a mutein thereof, or a fragment thereof is from about 2K to about 240K,
(11) The diagnostic agent for Sjögren's syndrome described in the above item (9) wherein said &agr;-fodrin, a mutein thereof, or a fragment thereof contains or comprises an amino acid sequence substantially shown by Arg-Gln-Lys-Leu-Glu-Asp-Ser-Tyr-Arg-Phe-Gln-Phe-Phe-Gln-Arg-Asp-Ala-Glu-Glu-Leu, ( SEQ ID NO:1)
(12) The diagnostic agent for Sjögren's syndrome described in the above item (11) wherein the molecular weight of &agr;-fodrin, a mutein thereof, or a fragment thereof is from about 100K to about 140K,
(13) A method for detection or assay of an antibody against &agr;-fodrin, a mutein thereof, a fragment thereof, or a salt thereof, which comprises contacting &agr;-fodrin, a mutein thereof, a fragment thereof, or a salt thereof with said antibody.
(14) A method for preventing or treating autoimmune disease which comprises administering to a patient a therapeutically effective amount of &agr;-fodrin, a mutein thereof, a fragment thereof, or a salt thereof with a pharmaceutically acceptable carrier,
(15) The method described in the above item (14), wherein autoimmune disease is Sjögren's syndrome,
(16) A method for diagnosing autoimmune disease which comprises detecting or assaying autoantibody against &agr;-fodrin, a mutein thereof, a fragment thereof, or a salt thereof, which comprises contacting &agr;-fodrin, a mutein thereof, a fragment thereof, or a salt thereof with said autoantibody,
(17) The method described in the above item (16), wherein autoimmune disease is Sjögren's syndrome,
(18) Use of &agr;-fodrin, a mutein thereof, a fragment thereof, or a salt thereof for the manufacture of a medicament for preventing or treating autoimmune disease,
(19) Use of &agr;-fodrin, a mutein thereof, a fragment thereof, or a salt thereof for the manufacture of a medicament for preventing or treating Sjögren's syndrome,
(20) Use of &agr;-fodrin, a mutein thereof, a fragment thereof, or a salt thereof for the manufacture of a medicament for diagnosing autoimmune disease, or
(21) Use of &agr;-fodrin, a mutein thereof, a fragment thereof, or a salt thereof for the manufacture of a medicament for diagnosing Sjögren's syndrome.
REFERENCES:
patent: 5118606 (1992-06-01), Lynch et al.
patent: 5182262 (1993-01-01), Leto
patent: WO 92/01935 (1992-02-01), None
Anderton et al. Immunology 2001. vol. 104 pp. 367-376.*
Karin et al. J. Exp Med vol. 180, pp. 2229-2237, 1994.*
Fox, Current Opi
Hayashi Yoshio
Sugino Hiromu
Edwards & Angell LLP
Hayashi Yoshio
Neuner George W.
Nolan Patrick J.
Umemuro Jun
LandOfFree
Composition containing &agr;-fodrin or &agr;-fodrin fragment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition containing &agr;-fodrin or &agr;-fodrin fragment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition containing &agr;-fodrin or &agr;-fodrin fragment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3284629